By Nqobile Dludla JOHANNESBURG (Reuters) -Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it ...

The lifetime risk of dementia after age 55 is about 42%, according to a recent study published in the journal Nature Medicine. Around 1 million adults in the U.S. are projected to develop dementia ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

California's low-cost insulin initiative, CalRx, faces delays, leaving diabetics without affordable options. State officials ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The ...

Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...

We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse ...

Lone Pine Capital, established in 1997 by Stephen Mandel, is a leading hedge fund and investment advisory firm based in ...

We recently published an article titled Jim Cramer Discusses These 10 Stocks & Says Bitcoin Created "Froth" In The Market. In ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...